tradingkey.logo

Clearpoint Neuro Inc

CLPT
View Detailed Chart
15.810USD
-2.420-13.27%
Close 11/07, 16:00ETQuotes delayed by 15 min
449.45MMarket Cap
LossP/E TTM

Clearpoint Neuro Inc

15.810
-2.420-13.27%
Intraday
1m
30m
1h
D
W
M
D

Today

-13.27%

5 Days

-31.91%

1 Month

-46.59%

6 Months

+10.95%

Year to Date

+2.80%

1 Year

+35.71%

View Detailed Chart

TradingKey Stock Score of Clearpoint Neuro Inc

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Clearpoint Neuro Inc's Score

Industry at a Glance

Industry Ranking
102 / 209
Overall Ranking
225 / 4614
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 2 analysts
Buy
Current Rating
29.000
Target Price
+83.43%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Clearpoint Neuro Inc Highlights

StrengthsRisks
ClearPoint Neuro, Inc. is a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. The Company’s flagship product is the ClearPoint Neuro Navigation System. Its initial product offering, the ClearPoint system, is an integrated system comprised of capital equipment and disposable products, designed to allow minimally invasive procedures in the brain to be performed in a magnetic resonance imaging (MRI) suite. The ClearPoint Array Neuro Navigation System and its principal disposable component is designed to be deployed in an operating room setting while also being usable in an MRI suite. It is engaged with healthcare and research centers in North America, Europe, Asia, and South America. It also provides solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 52.74% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 31.39M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 31.39M.
Undervalued
The company’s latest PE is -19.12, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 11.08M shares, increasing 2.83% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 13.85K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.61.

Clearpoint Neuro Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Clearpoint Neuro Inc Info

ClearPoint Neuro, Inc. is a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. The Company’s flagship product is the ClearPoint Neuro Navigation System. Its initial product offering, the ClearPoint system, is an integrated system comprised of capital equipment and disposable products, designed to allow minimally invasive procedures in the brain to be performed in a magnetic resonance imaging (MRI) suite. The ClearPoint Array Neuro Navigation System and its principal disposable component is designed to be deployed in an operating room setting while also being usable in an MRI suite. It is engaged with healthcare and research centers in North America, Europe, Asia, and South America. It also provides solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide.
Ticker SymbolCLPT
CompanyClearpoint Neuro Inc
CEOMr. Joseph Michael Burnett
Websitehttps://www.clearpointneuro.com/
KeyAI